See All Slides - tctmd.com

Slides

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

Presentation ACC 2012

First Pharmacogenomic Analysis Using Whole Exome Sequencing to Identify Novel Genetic Determinants of Clopidogrel

Presenter: Matthew Price

March 24, 2012

Presentation ACC 2012

RESET Study: Pharmacodynamic Effects of Switching Therapy in PCI Patients with High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose versus Prasugrel

Presenter: Gennaro Sardella

March 24, 2012

Presentation ACC 2012

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Presenter: Hyo-Soo Kim

March 24, 2012

Presentation ACC 2012

Long-Term Outcomes Following Transcatheter Aortic Valve Implantation: Insights on Prognostic Factors and Valve Durability from the Canadian Multicenter Experience

Presenter: Josep Rod?s-Cabau

March 24, 2012

Presentation ACC 2012

Economic Impact of Transradial Percutaneous Coronary Intervention

Presenter: David Safley

March 24, 2012

Presentation

Balloon-pump assisted Coronary Intervention Study (BCIS-1): Long term Mortality Data

Presenter: 130910|Divaka Perera

March 24, 2012

Presentation ACC 2012

Biodegradable Polymer Drug-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

Presenter: Robert A. Byrne

March 24, 2012

Presentation PCI Outcomes 2012

Controversy 3: In an Era of Increasing Governmental and Payer Oversight, Who Is Appropriate (and Not Appropriate) for PCI?

Presenter: Manesh R. Patel

March 23, 2012

Presentation PCI Outcomes 2012

Case 3: A Patient with Recurrent Stent Thrombosis

Presenter: Roxana Mehran

March 23, 2012

Advertisement

Slides

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

First Pharmacogenomic Analysis Using Whole Exome Sequencing to Identify Novel Genetic Determinants of Clopidogrel

RESET Study: Pharmacodynamic Effects of Switching Therapy in PCI Patients with High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose versus Prasugrel

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Long-Term Outcomes Following Transcatheter Aortic Valve Implantation: Insights on Prognostic Factors and Valve Durability from the Canadian Multicenter Experience

Economic Impact of Transradial Percutaneous Coronary Intervention

Balloon-pump assisted Coronary Intervention Study (BCIS-1): Long term Mortality Data

Biodegradable Polymer Drug-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

Controversy 3: In an Era of Increasing Governmental and Payer Oversight, Who Is Appropriate (and Not Appropriate) for PCI?

Case 3: A Patient with Recurrent Stent Thrombosis

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content